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Aim: To evaluate the effect of hyperthermia on cytostatic activity of chemotherapeutic drugs carboplatin, cisplatin, oxaliplatin, 
carmustine, gemcitabine and etoposide in human lymphoma cell culture. Methods: RAJI human lymphoma cells were incubated 
with cytostatics at 37 °C or 42 °C and evaluated for cell culture growth. Results: The number of viable cells after incubation with 
the drugs (except for gemcitabine) at 42 °C for 30 min was significantly lower than at 37 °C. There were synergism of cytostatic 
effects of platinum drugs (carboplatin, cisplatin and oxaliplatin) with cytostatic effect of 42 °C and the summation of cytostatic effect 
of carmustine or etoposide with the action of hyperthermia. The thermal enhancement ratio was 3.0 for oxaliplatin, 2.0 for cisplatin, 
1.8–2.4 for carboplatin. The combination of platinum drugs with gemcitabine resulted in a significant enhancement of cytostatic 
activity. Conclusion: Our findings suggest that a gain in sensitivity of RAJI human lymphoma cells to platinum drugs occurs at 42 °C.
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Intrinsic drug resistance of tumor cells or t�at 
acquired during t�e c�emot�erapy is considered 
to be t�e main cause of failures in t�e treatment 
of malignant tumors. Overcoming of t�e tumor drug 
resistance may open new perspectives in t�e man-
agement of patients for w�om standard t�erapeutic 
approac�es are ineffective.
To overcome t�e c�emoresistance� different 
p�ysicoc�emical modalities are currently used t�at 
can selectively en�ance t�e sensitivity of tumor cells 
to anticancer t�erapy. Hypert�ermia is regarded as t�e 
most promising modifying factor. It s�ould also take 
into account t�e important fact of direct damaging 
effect of �eat on t�e tumor.
T�e clinical experience gained until now confirms 
t�ese t�eoretical prerequisites. Encouraging results 
of w�ole-body �ypert�ermia are ac�ieved in c�emo-
t�erapy for disseminated melanoma [�]� metastatic 
sarcoma [�]� recurrent ovarian cancer [��4]� pleural 
mesot�elioma [5]� malignant tumors in c�ildren [6] 
and ot�er types of tumors [7���]. In a number of cases 
�ypert�ermia makes it possible to reduce t�e doses 
of administered cytostatics by up to 5�% wit� concur-
rent en�ancement of antitumor effect and decrease 
of nep�rotoxic� cardiotoxic and �epatotoxic effects 
of t�e c�emot�erapeutic agents.
In experimental models of various tumors� ampli-
fication of cytostatic antitumor effect wit� increased 
temperature was demonstrated. Numerous studies 
of tumor cell cultures reported increased cytotoxicity 
of cyclop�osp�amide� melp�alan� ifosfamide� nitro-
sourea� bleomycin� doxorubicin� platinum prepara-
tions� etoposide� vincristine� taxanes� gemcitabine 
[����5]. T�e deat� of tumor cells induced by cyto-
statics was found to rise wit� elevated temperature 
and prolonged duration of �eating� and t�e �ig�est-
cytotoxicity was recorded wit� concurrent exposure 
to a c�emot�erapeutic agent and �ypert�ermia.
T�e mec�anism of en�ancing antitumor activity 
of c�emot�erapeutic agents at elevated temperature 
�as not been definitively determined. T�e available 
findings suggest t�at permeability of cell membranes 
and penetration of drugs into tumor cells are improved� 
and t�at t�e mec�anisms of repair of primary and 
secondary damage of tumor cells are in�ibited [�6].
Notably� t�e results of experimental studies inves-
tigating t�e interaction between �ypert�ermia and cy-
tostatic drugs are quite contradictive. T�e use of vari-
ous cell lines and experimental tumors� treatment 
regimens� temperature levels and drug concentrations 
makes it difficult to interpret t�e results of t�e studies.
Investigation of possible t�ermal en�ancement 
of �uman lymp�oma cell sensitivity to cytostatic drugs 
used in t�e management of t�e disease is of interest 
for t�e development of t�ermoc�emot�erapy sc�emes 
for malignant lymp�omas. T�e objective of t�is study 
was investigation of t�e effect of �ypert�ermia on t�e 
cytostatic activity of c�emot�erapeutic agents used 
in t�e treatment of malignant lymp�oma; t�e investiga-
tion was conducted on RAJI �uman lymp�oma cell line.
MATERIALS AND METHODS
Chemotherapeutic drugs. T�e effect of t�e 
following c�emot�erapeutic agents was evaluated: 
carboplatin �c�emocarb� Dabur P�arma Ltd.� In-
dia��  oxaliplatin �eloxatin� Sanofi-Wint�rop Industria� 
France�� cisplatin �cytoplatin� CIPLA Ltd.� India�� 
carmustine �BiCNU� Bristol-�eiers Squibb� Italy�� 
etoposide �etoposide-Ebewe� Austria�� gemcitabine 
�citogem� Dr. Reddy’s Laboratories Ltd.� India�. T�e 
drugs were diluted wit� saline or distilled water for 
injections according to t�e package insert instructions� 
just before t�e experiment.
Cell culture. T�e investigations were conducted 
on RAJI �uman lymp�oma cell line �Russian Collection 
of Cell Cultures� Cytology Institute of Russian Acad-
emy of Sciences� St. Petersburg�. T�e cell culture was 
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grown in RP�I-�64� culture medium supplemented 
wit� ��% fetal calf serum.
Cell treatment. To perform t�e experiments� t�e 
cell culture was plated in culture vials� ������� cells 
in � ml of t�e culture medium in eac�. Twenty-four �ours 
later 5����� µl of cytostatic solution were added into 
t�e vials for different final concentrations. T�e vials wit� 
t�e cell culture were incubated in �eating bat� circulator 
EXATER� U� �Julabo� Germany� at �7 °C or 4� °C for 
�5 or �� min and for 48 � in t�e t�ermostat at �7 °C. After 
adding �.�% trypan blue to t�e suspension� live �un-
stained� cells were counted in �emocytometer. T�ree 
vials wit� cells were used for eac� drug concentration.
Regression analysis of t�e data was employed 
to calculate t�e rate of growt� in�ibition of t�e tu-
mor cell culture �IC5� — drug concentration resulting 
in growt� in�ibition by 5�% versus t�e control�. T�er-
mal en�ancement ratios �TER� for in�ibition of cell 
proliferation for eac� c�emot�erapeutic drug were 
calculated as IC5� for drug alone divided by IC5� for 
drug combined wit� �ypert�ermia [�7].
T�e values obtained were processed using stand-
ard statistical met�ods of Origin 7.�.
RESULTS AND DISCUSSION
T�e study of RAJI �uman lymp�oma cell culture 
growt� demonstrated t�at t�e effect of 4� °C tem-
perature was more prominent wit� increased duration 
of �eating. T�e �eating of t�e cells for �5 min did not 
actually affect t�e number of viable cells� w�ereas t�e 
increase in t�ermal treatment duration up to �� and 
6� min resulted in t�e reduction of viable cell numbers 
to 64% and 4�%� respectively.
Fig. � presents t�e results of RAJI �uman lym-
p�oma cells incubation wit� c�emot�erapeutic agents 
at different concentrations in temperature settings 
of �7 °C or 4� °C for �5 and �� min. T�e findings sug-
gest t�at examined drugs induce significant in�ibition 
of �uman lymp�oma cell culture growt� at �7 °C� wit� 
growing cytostatic effect upon increasing t�e final 
concentration of t�e drug in t�e culture medium. T�e 
calculation of cytostatic activity rate �IC5�� demonstrated 
t�at RAJI �uman lymp�oma cell culture at �7 °C is most 
sensitive to etoposide �IC5� = �.� µg/ml�� oxaliplatin 
�IC5� = �.� µg/ml� and cisplatin �IC5� = �.8 µg/ml�. 
IC5� was 8.5 µg/ml for carboplatin� �.� µg/ml for car-
mustine and 6.5 µg/ml for gemcitabine �Table ��.
Table 1. Cytostatic activity of chemotherapeutic agents at 37 оС and hy-
perthermia setting
Agent IC5�, µg/ml37 °С  42 °С, 15 min 42 °С, 30 min
Cisplatin 0.8 0.4 (TER = 2.0) 0.4 (TER = 2.0)
Carboplatin 8.5 4.8 (TER = 1.8) 3.6 (TER = 2.4)
Oxaliplatin 0.3 0.1 (TER = 3.0) 0.1 (TER = 3.0)
Carmustine 9.3 8.9 (TER = 1.0) 9.2 (TER = 1.0)
Gemcitabine 6.5 4.7 (TER = 1.4) 8.4 (TER = 0.8)
Etoposide 0.1 0.1 (TER = 1.0) 0.1 (TER = 1.0)
Incubation of RAJI �uman lymp�oma cells wit� 
oxaliplatin at 4� °C for �5 min resulted in significant 
reduction of cell number compared to �7 °C. Effective-
ness of gemcitabine and etoposide was not c�anged� 
and t�e en�ancement of t�e effect of carboplatin� 
cisplatin and carmustine at 4� °C for �5 min was ob-
served only at certain concentrations of t�e drug. Cell 
incubation at 4� °C for �� min significantly increased 
t�e efficiency of all investigated drugs� except for 
gemcitabine �Fig. ��.
T�e calculation of cell culture growt� in�ibition using 
IC5� criterion and taking into account t�e reduced num-
ber of cells due to t�e effect of increased temperature 
alone demonstrated t�at synergetic amplification of t�e 
cytostatic effect by �ypert�ermia occurred wit� oxali-
platin� carboplatin and cisplatin: drug IC5� decreased 
from �.� at �7 °C to �.� µg/ml at 4� °C for oxaliplatin� 
from 8.5 to 4.8��.6 µg/ml for carboplatin� and from 
�.8 to �.4 µg/ml for cisplatin. Summation of drug and 
�ypert�ermia effects was observed wit� carmustine and 
etoposide� as drug IC5� did not c�ange. Hypert�ermic ex-
posure wit� gemcitabine produced a small amplification 
of cell growt� in�ibition wit� �5 min duration of �eating 
�IC5� decreased from 6.5 to 4.7 µg/ml compared to t�at 
at �7 °C� or reduction of t�e effect wit� �� min duration 
of �eating �IC5� increased from 6.5 to 8.4 µg/ml com-
pared to t�at at �7 °C�. T�e t�ermal en�ancement 
ratio �TER� of t�e cytostatic effect �t�e ratio of drug 
IC5� at �7 °C to IC5� at 4� °C� was �.� for oxaliplatin� 
�.� for cisplatin� �.8��.4 for carboplatin� �.� for car-
mustine� �.� for etoposide. T�e TER for gemcitabine 
was �.4 wit� �5 min duration of �eating. T�e increase 
in �eating duration up to �� min resulted in gemcitabine 
effect reduction �see Table ��. T�e differences between 
t�e effects at t�e temperatures of �7 °C and 4� °C for 
all platinum preparations were statistically significant.
T�e data obtained suggest t�at lymp�oma cells 
growt� in�ibition by alkylating c�emot�erapeutic 
agents carboplatin� cisplatin� oxaliplatin� carmustine 
and plant-derived drug etoposide increases under 
�ypert�ermia. For platinum drugs synergetic activ-
ity wit� �ypert�ermia was observed� for carmustine 
or etoposide t�ere was t�e summation of cytostatic 
effects of drug and �ypert�ermia.
It s�ould be noted t�at t�ere are contradictory 
reports about t�e interaction of �ypert�ermia and 
gemcitabine. Simultaneous application of gemcitabine 
and �eating led to t�e decreased cytotoxicity [�6� ��]� 
�ad no influence on cytotoxicity [��] or augmented 
cytotoxic effect of t�e drug [��� �8� ��]. Our data did 
not allow to consider gemcitabine as a promising drug 
for t�ermoc�emot�erapy of lymp�omas. But as gem-
citabine in combination wit� platinum drugs is used for 
t�e treatment of refractory lymp�oma� we investigated 
t�e effect of �ypert�ermia on t�e cytostatic effect 
of t�is combination.
T�e data presented on Fig. � indicate t�at t�e 
combination of platinum drugs wit� gemcitabine 
�5 µg/ml� at t�e temperature of �7 °C results in signifi-
cant in�ibition of RAJI �uman lymp�oma cell culture 
growt�� t�e effect of cytostatics increasing wit� t�e 
rise of t�e final concentration of platinum agents. 
A convincing corroboration of antitumor effect en-
�ancement is t�e reduction of drug IC5�. W�ile IC5� for 
cisplatin alone was �.8 µg/ml� for carboplatin alone 
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8.5 µg/ml� and for oxaliplatin alone �.� µg/ml �see 
Table ��� it decreased to �.�6 µg/ml for cisplatin wit� 
gemcitabine �5 µg/ ml�� to �.5 µg/ml for carboplatin 
wit� gemcitabine� and to �.�� µg/ml for oxaliplatin 
wit� gemcitabine �Table  ��. T�us� cytostatic activity 
of platinum preparations in combination wit� gem-
citabine increased ��-fold for cisplatin� �7-fold for 
carboplatin� and ��-fold for oxaliplatin. Gemcitabine 
alone �5 µg/ml� at �7 °C reduced t�e number of RAJI 
�uman lymp�oma cells only �-folds. T�us� we can 
conclude about t�e synergistic action of gemcitabine 
wit� t�e platinum drugs at �7 °C.
Incubation of t�e cells wit� platinum drugs in com-
bination wit� gemcitabine at 4� °C for �5 min virtually 
did not affect t�e cytostatics activity compared to t�at 
at �7 °C. T�e increased duration of cell incubation 
at 4� °C up to �� min led to t�e reduction in t�e number 
of viable cells compared to t�e numbers observed 
at �7 °C �Fig. ��. T�e calculation of cytostatic effect 
rates for platinum drugs� taking into account t�e re-
duced number of cells due to t�e effect of increased 
temperature alone� demonstrated t�at it was t�e case 
of summation of cytostatic effect of platinum drugs 
wit� gemcitabine and cytostatic effect of �ypert�ermia 
as drug’s IC5� did not actually c�ange after exposure 
to �ypert�ermia �see Table ��.
Table 2. Cytostatic activity of platinum drugs in combination with gem-
citabine
Drugs IC5�, µg/ml37 °С 42 °С, 15 min 42 °С, 30 min
Gemcitabine + cisplatin 0.06 0.06 0.05
Gemcitabine + carboplatin 0.5 0.5 0.4
Gemcitabine + oxaliplatin 0.03 0.03 0.03
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Fig. 1. Cytostatic effect related to drug concentration and cell incubation temperature
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Fig. 2. T�e impact of �ypert�ermic exposure �4� °C� �5 or �� min� 
and gemcitabine �5 µg/ml� on cytostatic effect of platinum drugs
T�e results of t�e study allowed to assert t�at growt� 
in�ibition of RAJI cells by carboplatin� cisplatin� oxali-
platin� carmustine and etoposide was increased by t�e 
exposure to 4� °C for �� min. Summation of drug and 
�ypert�ermia cytostatic effects was observed for car-
mustine and etoposide� synergic effect — for all plati-
num drugs. T�e t�ermal en�ancement ratio was �.� for 
oxaliplatin� �.� for cisplatin and �.8��.4 for carboplatin.
T�e combination of platinum agents wit� gem-
citabine at �7 °C produces a synergic effect of t�e 
cytostatics. In suc� combination� IC5� of platinum 
drugs was reduced ��-fold for oxaliplatin� ��-fold for 
cisplatin� �7-fold for carboplatin. Incubation of t�e cells 
wit� platinum preparations in combination wit� gem-
citabine at 4� °C for �� min causes a reduction in t�e 
number of viable cells compared to cell incubated 
at �7 °C� w�ic� is a result of summation of cytostatic 
effects of drugs and �ypert�ermia.
T�e obtained results give grounds to continue 
t�e study on animal models wit� feasible prospects 
of clinical application.
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